- Report
- August 2025
- 196 Pages
Global
From €3127EUR$3,545USD£2,711GBP
€3474EUR$3,939USD£3,012GBP
- Report
- January 2026
- 185 Pages
Global
From €3127EUR$3,545USD£2,711GBP
€3474EUR$3,939USD£3,012GBP
- Report
- February 2026
- 250 Pages
Global
From €3960EUR$4,490USD£3,434GBP
- Report
- February 2026
- 250 Pages
Global
From €3960EUR$4,490USD£3,434GBP
- Report
- February 2026
- 250 Pages
Global
From €3960EUR$4,490USD£3,434GBP
- Report
- February 2026
- 250 Pages
Global
From €3960EUR$4,490USD£3,434GBP
- Report
- December 2025
- 200 Pages
Global
From €7012EUR$7,950USD£6,080GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2460EUR$2,789USD£2,133GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3175EUR$3,600USD£2,753GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4190EUR$4,750USD£3,633GBP
- Report
- March 2025
- 145 Pages
Global
From €4278EUR$4,850USD£3,709GBP
Glyburide is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sulfonylureas, which work by stimulating the pancreas to produce more insulin. Glyburide is used to help control blood sugar levels in people with type 2 diabetes. It is usually taken once or twice a day with meals.
Glyburide is a widely used drug in the Endocrine and Metabolic Disorders Drugs market. It is used to treat type 2 diabetes, a condition that affects millions of people worldwide. It is a cost-effective and well-tolerated drug, making it a popular choice for many patients. It is also available in generic form, which further reduces the cost of treatment.
Some companies in the Glyburide market include Merck & Co., Inc., Sanofi, Novo Nordisk, and Eli Lilly and Company. Show Less Read more